Azopharma Product Development Group, Inc. has opened a new facility in South Florida. The new 22,000-sq.-ft. facility will house the company’s formulation development services, small-scale manufacturing, development services and specialized analytical services, as well as Azopharma’s new drug delivery company, ApiCross. The expanded facility allows for small scale manufacturing from 30 Kg to 50 Kg.

According to Phil Meeks, chief executive officer of Azopharma, “Our new facility allows us to expand our service offerings and take on larger scale projects to meet the needs of our pharmaceutical, biotechnology and medical device clients.”

The facility supports formulation development services including semi-solids, liquids, solids, multi-layer tablets, lotions/creams, gels, transdermal patches, cytotoxic and highly potent compound development services.  

This new facility allows Azopharma to provide the full spectrum of development services required to be a leader in the industry. Mr. Meeks continued, “Azopharma Product Development Group is only one of a few organizations in the U.S. that are capable of developing a full spectrum of dosage forms from discovery through commercialization. By bringing together the best scientists in the field, state-of-the-art facilities and our focus on quality means that we can provide our partners a winning combination in total product development.”